dc.contributor.author | Purnak, Tuğrul | |
dc.contributor.author | Beyazıt, Yavuz | |
dc.contributor.author | Öztas, Erkin | |
dc.contributor.author | Yesil, Yusuf | |
dc.contributor.author | Efe, Cumali | |
dc.contributor.author | Torun, Serkan | |
dc.contributor.author | Çelik, Tugrul | |
dc.contributor.author | Tenlik, Ilyas | |
dc.contributor.author | Kurt, Mevlüt | |
dc.contributor.author | Özaslan, Ersan | |
dc.date.accessioned | 2019-12-10T11:20:28Z | |
dc.date.available | 2019-12-10T11:20:28Z | |
dc.date.issued | 2012 | |
dc.identifier.issn | 1470-3203 | |
dc.identifier.uri | https://doi.org/10.1177/1470320311434241 | |
dc.identifier.uri | http://hdl.handle.net/11655/15334 | |
dc.description.abstract | Background and aims: Hepatitis B virus (HBV) infection is a public health problem and affects nearly 350 million people worldwide. The present study was conducted in order to investigate the role of circulating angiotensin-converting enzyme (ACE) in the context of renin-angiotensin-aldosterone in newly diagnosed chronic hepatitis B infection. Moreover the association between liver fibrosis and serum ACE levels was also investigated. Materials and methods: The study was performed on 50 chronic hepatitis B (CHB) patients (24 males, 26 females; median age 39.4 years, range 18-63) and 20 healthy controls. The clinical features of CHB patients including demographics, laboratory and liver biopsy findings were summarized. Serum ACE levels were measured by using commercially available kits. Results: Serum median ACE levels were 48.4 (14-83) U/L and 26.2 (12-48) U/L for the CHB patients and controls, respectively. Serum ACE levels were significantly higher in patients with CHB compared with the control group (p<0.001). Twenty-two patients (44%) had advanced liver fibrosis (Ishak score >2) and 28 patients (56%) had mild liver fibrosis (Ishak score <= 2). Mean serum levels of ACE were significantly higher among patients with advanced fibrosis as compared with those without advanced fibrosis (60.3 +/- 14.2 U/L vs. 39.0 +/- 10.5 U/L, p<0.001). Receiver operating characteristic (ROC) curve analysis suggested that the optimum ACE level cut-off point for advanced fibrosis was 52.5 U/L (sensitivity: 81.8%, specificity: 82.1%, PPV 78.3%, NPV 85.2%, accuracy 82%, AUC: 0.890). Conclusions: Our study showed that elevated circulating ACE levels are commonly observed in CHB patients. This finding was more prominent in patients with advanced fibrosis in liver. When evaluating a patient along with other parameters, the inclusion of ACE levels in the evaluation of CHB patients may grant additional prognostic information. | |
dc.language.iso | en | |
dc.publisher | Sage Publications Inc | |
dc.relation.isversionof | 10.1177/1470320311434241 | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | Cardiovascular System & Cardiology | |
dc.title | Serum Angiotensin-Converting Enzyme Level As A Marker of Fibrosis in Patients with Chronic Hepatitis B | |
dc.type | info:eu-repo/semantics/article | |
dc.type | info:eu-repo/semantics/publishedVersion | |
dc.relation.journal | Journal Of The Renin-Angiotensin-Aldosterone System | |
dc.contributor.department | İç Hastalıkları | |
dc.identifier.volume | 13 | |
dc.identifier.issue | 2 | |
dc.identifier.startpage | 244 | |
dc.identifier.endpage | 249 | |
dc.description.index | WoS | |
dc.description.index | Scopus | |